{"entity":{"id":"nct05759728","kind":"trial","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of CNA3103: 5 x 10^7 cells in colorectal cancer, run by Carina Biotech Limited, now recruiting.","summary":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05759728 by Carina Biotech Limited, with 45 participants planned, started 2023-10-24 and due to reach its primary completion in 2027-12. Interventions recorded: CNA3103: 5 x 10^7 cells, CNA3103: 1.5 x 10^8 cells, CNA3103: 4.5 x 10^8 cells, CNA3103: 1.5 x 10^9 cells, CNA3103: 2.5 x 10^7 cells and CNA3103: 6.75 × 10^8 cells.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05759728","url":"https://clinicaltrials.gov/study/NCT05759728"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05759728","phase":"1/2","setting":"A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer","sponsor":"Carina Biotech Limited","enrolled":45,"outcomes":[]},"route":"/trials/nct05759728/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}